Important note
This AI stock analysis for Moderna is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
Moderna - AI Stock Analysis
Analysis generated March 13, 2025
Moderna, Inc. is a biotechnology company that has garnered significant attention for its development of the mRNA technology platform. This platform is used to create vaccines and therapeutics, with their COVID-19 vaccine, mRNA-1273, being a notable success. The entity primarily focuses on pioneering mRNA science to address potentially severe diseases beyond COVID-19, including oncology, cardiology, infectious diseases, and rare genetic diseases.
Fundamental Analysis
Revenue: Moderna reported a revenue of $1.85 billion for the last quarter, which represents a quarterly increase of 746.58% and a year-over-year increase of 3.11%. These numbers signify robust growth in both the short-term and long-term.
Net Income: The company achieved a net income of $13 million, which shows a quarterly increase of 101.02% and a year-over-year increase of 100.36%. The major uptick in net income illustrates improving profitability.
EBITDA: EBITDA for the last quarter came in at $18 million, an increase of 98.64% from the previous quarter and 98.98% compared to the same quarter last year. This metric indicates significant operational efficiency.
PE Ratio: The Price to Earnings (P/E) ratio is 24.73, suggesting that the stock is trading within a reasonable range and neither presents an overvalued nor undervalued status.
Technical Analysis
Stock Price: The current stock price is $35.26, reflecting a 10.46% increase compared to a month ago. This short-term upward trend is a positive indicator for potential near-term gains. However, the stock has declined by 65.92% compared to a year ago, which could pose long-term risk concerns.
Simple Moving Average (SMA10): The current 10-day Simple Moving Average (SMA10) is 34.67, higher than the previous SMA10 of 34.17. This suggests an upward trend in the stock price.
Relative Strength Index (RSI): The RSI is at 57.3, which indicates a neutral condition. This means the stock is neither overbought nor oversold, preserving a balanced momentum.
Alternative Data Analysis
Job Postings and Employee Sentiment: Moderna has 143 open positions, a reduction of 27% over the last couple of months, indicating potential cost-cutting measures. Employee sentiment is relatively low, with only 43% expressing a positive outlook, a decline of 9% recently, which is concerning for long-term workplace morale.
Customer Acquisition: Moderna’s website has had approximately 190,000 visitors, showing a decline of 37% over the last couple of months. This downward trend suggests a waning interest or loss in customer engagement.
Customer Engagement: Moderna’s Twitter has 150,000 followers, down by 1% recently, signaling a slight loss of public interest.
AI Predictive Score: According to AltIndex’s AI score, which evaluates based on fundamental, technical, and alternative data, Moderna has a score of 33 - a sell signal.
Conclusion and Recommendation
Considering the various aspects of Moderna’s performance, the company demonstrates significant revenue and income growth, evident in their quarterly and yearly increases. While current technical indicators suggest a positive short-term trend, the long-term performance suggests careful deliberation is required. The decline in job postings, employee sentiment, web traffic, and social media engagement combined with an AI score of 33, signaling a ‘sell’ verdict, raises caution about future prospects.
In conclusion, potential investors should weigh the promising financial performance against the slightly negative indicators from alternative data insights and long-term stock price trends.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
